Nyxoah SA (EBR:NYXH)

Belgium flag Belgium · Delayed Price · Currency is EUR
5.63
+0.33 (6.23%)
Last updated: Oct 9, 2025, 12:45 PM CET
6.23%
Market Cap198.41M
Revenue (ttm)4.93M
Net Income (ttm)-77.20M
Shares Out37.44M
EPS (ttm)-2.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume35,955
Average Volume113,376
Open5.43
Previous Close5.30
Day's Range5.35 - 5.63
52-Week Range3.84 - 10.90
Beta0.58
RSI60.79
Earnings DateNov 13, 2025

About Nyxoah

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. [Read more]

Sector Healthcare
Founded 2009
Employees 184
Stock Exchange Euronext Brussels
Ticker Symbol NYXH
Full Company Profile

Financial Performance

In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.

Financial Statements

News

There is no news available yet.